Search

Displaying results 8021 - 8030 of 10000 in total
  1. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

  2. Drug

    Virginiamycin M1

    go.drugbank.com/drugs/DB01669
    Experimental

    Pristinamycin IIA is a macrolide antibiotic, a member of the streptogramin A group of antibiotics, and one component of pristinamycin. It is produced by Streptomyces graminofaciens and other bacteria.

  3. Drug

    Ridaforolimus

    go.drugbank.com/drugs/DB06233
    Investigational

  4. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  5. Drug

    Aprinocarsen

    go.drugbank.com/drugs/DB06451
    Investigational

    Aprinocarsen is a specific antisense oligonucleotide inhibitor of protein kinase C-alpha.

  6. Drug

    Pegademase

    go.drugbank.com/drugs/DB00061
    ApprovedWithdrawn

    Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.

  7. Drug

    Benzophenone

    go.drugbank.com/drugs/DB01878
    Approved

    Benzophenone is the organic compound. Substituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.

  8. Drug

    Fisogatinib

    go.drugbank.com/drugs/DB16167
    Investigational

    Fisogatinib is under investigation in clinical trial NCT04194801 (A Phase Ib/ii Study of Fisogatinib(blu-554) in Subjects With Hepatocellular Carcinoma).

  9. Drug

    TPI-ASM8

    go.drugbank.com/drugs/DB05572
    Investigational

    TPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.

  10. Drug

    CVT-6883

    go.drugbank.com/drugs/DB05936
    Experimental

    CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation

    Categories: Adenosine A2 Receptor Antagonists